Articles tagged "Viral therapy"

2021 American Transplant Congress
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
Z. A. Yetmar¹, E. Beam¹, J. C. O'Horo¹, R. Ganesh², D. M. Bierle², L. Brumble³, M. T. Seville⁴, R. R. Razonable¹
¹Infectious Diseases, Mayo Clinic, Rochester, MN, ²General Internal Medicine, Mayo Clinic, Rochester, MN, ³Infectious Diseases, Mayo Clinic, Jacksonville, FL, ⁴Infectious Diseases, Mayo Clinic, Scottsdale, AZ
*Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…
2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
G. Gupta, I. Yakubu, P. Kimball, L. Kang, K. Mitchell, M. Shinbashi, D. Kumar, I. Moinuddin, L. Kamal, A. King, C. Bhati, M. Levy, A. Cotterell, A. Sharma, R. Sterling
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
2021 American Transplant Congress
Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective
M. L. Holt, A. James, K. Gutierrez, T. Sparkman, J. Banbury, D. Jones
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Due to direct acting antivirals (DAAs), hepatitis C virus (HCV) positive patients are now resources for organ transplantation in HCV negative recipients. Our institution…
2021 American Transplant Congress
The Use of Hcv Nat+ Organs in Hcv Negative Recipients with On-site Specialty Pharmacy Services: A Win for the Patient, the Transplant Center, and Society?
M. Person, N. Patel, W. Simerlein, H. Meadows, D. DuBay, D. Taber
Medical University of South Carolina, Charleston, SC
*Purpose: Use of HCV AB positive organs (HCV AB+) with active viremia (NAT+) relies on appropriate and timely use of direct acting antiviral therapies (DAA).…
2021 American Transplant Congress
Influence of Immunosuppressant Management on Mortality in Kidney Transplant Recipients Hospitalized with COVID-19
Y. Fenig, A. Santeusanio, M. Menon, C. Liu, M. Rana, R. Shapiro
Mount Sinai Hospital, New York, NY
*Purpose: Kidney transplant recipients are thought to be at high risk for mortality from COVID-19 due to the necessity for chronic immunosuppressive therapy to prevent…
2021 American Transplant Congress
Current Practices for Management and Treatment of COVID-19 in Immunocompromised Adults: A Survey of Institutions
H. H. Nam¹, S. Aslam², O. Beaird³, G. Forrest⁴, M. Fung⁵, A. Limaye⁶, A. Multani³, J. Nelson⁷, R. Rakita⁶, L. Strasfeld⁸, J. Schaenman³
¹Medicine, University of California - Irvine, Orange, CA, ²Division of Infectious Diseases and Global Public Health, University of California - San Diego, San Diego, CA, ³Medicine, University of California - Los Angeles, Los Angeles, CA, ⁴Medicine, Rush University, Chicago, IL, ⁵Medicine, University of California - San Francisco, San Francisco, CA, ⁶Medicine, University of Washington, Seattle, WA, ⁷Medicine, Stanford University, Palo Alto, CA, ⁸Medicine, Oregon Health and Science University, Portland, OR
*Purpose: The optimal testing strategy for solid organ transplantation (SOT) donor and recipient evaluation, as well as treatment for COVID-19 is unknown. We assessed the…
2021 American Transplant Congress
Delayed Valganciclovir Initiation and the Incidence of Cytomegalovirus Infection in Liver Transplant Recipients
S. Shaikh, P. Kawewat-Ho, Y. Genyk, L. Sher, J. Kahn, L. Rivera
Keck Medical Center of USC, Los Angeles, CA
*Purpose: Opportunistic infections remain a significant burden after liver transplantation, particularly cytomegalovirus (CMV) infection. With the use of valganciclovir (VGCV), the incidence of CMV infection…
2021 American Transplant Congress
Clinical Characteristics, Risk Factors and Outcomes of Norovirus Infection in Renal Transplant Patients: A Retrospective Single Center Study
T. Brooks¹, T. Crilley¹, B. Gaglani², N. Jakharia²
¹Department of Internal Medicine, Wake Forest University Baptist Medical Center, Winston Salem, NC, ²Division of Infectious Diseases, Wake Forest University Baptist Medical Center, Winston Salem, NC
*Purpose: Norovirus gastrointestinal infection has been identified as a cause of significant morbidity among immunocompromised hosts, particularly hematopoietic stem cell transplant (HSCT) and solid organ…
2021 American Transplant Congress
Evaluation of Low Dose Famciclovir as Herpes Simplex Virus and Varicella Zoster Virus Prophylaxis in Cytomegalovirus Low Risk Solid Organ Transplant Recipients
M. Cote, A. Cubley, C. Rogers, S. Shao, C. N. Kotton
Massachusetts General Hospital, Boston, MA
*Purpose: Famciclovir is recommended for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low risk (both donor and recipient CMV seronegative)…
2021 American Transplant Congress
Clinical Outcomes and Management of Covid-19 Patients Among Kidney Transplant Recipients: A Systematic Review
S. Ismail¹, A. Babonj², S. Al Harbi³, A. Babonj², A. Almalki¹, E. J. Murray⁴
¹King Khalid hospital, MNGHA, Jeddah, Saudi Arabia, ²King Abdulaziz University, Jeddah, Saudi Arabia, ³King Faisal Specialist Hospital, Jeddah, Saudi Arabia, ⁴Boston University School of Public Health, Boston, MA
*Purpose: We aim to systematically review published literature and synthesize the evidence available on therapeutic interventions and clinical outcomes used in the management of COVID-19…